Kate Middleton’s diagnosis reminds us that early detection is key

Home - General

Kate Middleton’s diagnosis reminds us that early detection is key

Kate Middleton’s recent cancer diagnosis has highlighted the importance of early detection to us all. Detecting potential health issues early means individuals can work with healthcare professionals to implement treatment plans, lifestyle changes, or preventative measures. These could mitigate, or even prevent the progression of certain diseases.


An article published by the Daily Mail, which focuses on early cancer detection MOT’s, emphasises the importance of preventative testing and treatment throughout. Charlotte Griffiths, who underwent our Everywoman Plus Tumour-Associated Markers test, stated that it is vital to keep a watchful eye for any unexpected bodily changes, such as unexplained bumps or weight loss, which may indicate a presence of cancer.

At Randox Health, we test for a range of different tumour markers, as well as genetic testing, to deliver information on cancer risk to an individual. This aims to empower people to be proactive towards improving their health and makes them aware of any potential future health risks they may have.

It is estimated that 30-50% of all cancer cases are avoidable, and in many cases, early detection is key and can save lives. Cancer that’s diagnosed at an early stage, when it isn’t too large and hasn’t spread, is more likely to be treated successfully.

Spotting cancer at an early stage can save lives, however many people do not have access to the information or services to facilitate this detection. Over 8 million people in the UK are currently awaiting diagnostic testing. At Randox Health, with over 40 years’ experience in working towards improving healthcare worldwide, we have a focus on preventative healthcare; aiming to achieve better health outcomes whilst reducing the burden on clinical services.

At Randox Health we offer genetic risk tests for inherited cancers, including Breast and Ovarian CancerBowel Cancer, and others. In addition, we offer a range of full-body health tests that include common tumour-associated markers.

The results from your tests allow you to get a more accurate representation of your current health status, as well as giving you the ability to make lifestyle changes to potentially prevent future health risks.

Discover our health checks at randoxhealth.com

0324 Cancer Risk - Social

Biomedical Science Day 2023

This 8th June, Randox is celebrating Biomedical Science Day and our vital role in pro-active healthcare through our Randox Health Clinics.

Biomedical Science Day celebrates the vital role biomedical scientists play in patient care through the diagnosis of infections and diseases. It is a national event organized by the Institute of Biomedical Science (IBMS), the professional body for biomedical scientists and laboratory support staff. The awareness day aims to inform the public and empower patients by telling them about practices in biomedical science and celebrating a profession that is #AtTheHeartOfHealthcare.

Biomedical science is practiced in healthcare laboratories to identify, research, monitor and treat diseases. As one of the broadest areas of modern science, it focuses on the complexity of the human body and underpins much of modern medicine.

Here at Randox we continuously celebrate all our laboratory staff on a global scale – our team consists of over 650 research scientists and engineers who work in four jurisdictions across three continents!

For over forty years, Randox laboratory staff have been contributing to our work in preventative healthcare and research into diagnostics.

Randox has many departments which all work collectively to produce results. Our laboratory and R&D scientists are continuously researching new biomarker discovery. With a driven commitment to improving health worldwide, Randox reinvest up to 25% of turnover into developing disruptive innovations in diagnostics and healthcare – providing earlier diagnosis, prognosis, and improved patient risk to reduce current invasive diagnostic methods.

“Here at Randox we are using cutting edge Research and Technologies with the aim of making a difference in the field of Clinical Diagnostics and preventative healthcare.”

– Dr. Sarah Gildea, Senior R&D Scientist at Randox Teoranta 


World Heart Day 2022

World Heart Day 2022

World Heart Day – Raising awareness of Cardiovascular Diseases

On 29th September, World Heart Day is an opportunity for everyone to stop and consider how best to use heart for humanity, for nature, and for yourself. Beating cardiovascular disease is something that matters to every beating heart.

In May 2012, world leaders committed to reducing global mortality from non-communicable diseases (NCDs) by 25% by 2025. Cardiovascular disease (CVD) is accountable for nearly half of all NCD deaths making it the world’s number one killer. World Heart Day is, therefore, the perfect platform for the CVD community to unite in the fight against CVD and reduce the global disease burden.

World Heart Day is a global campaign created by the World Heart Federation in which it informs people around the globe that CVD, including heart disease and stroke, is the world’s leading cause of death claiming 18.6 million lives each year. It aims to highlight the actions that individuals can take to prevent and control CVD as well as to drive action to educate people by controlling risk factors such as tobacco use, unhealthy diet, and physical inactivity.

What are cardiovascular diseases?

Cardiovascular diseases (CVDs) are a group of disorders relating to the heart and blood vessels and they include:

  • coronary heart disease – disease of the blood vessels supplying the heart muscle
  • cerebrovascular disease – disease of the blood vessels supplying the brain
  • peripheral arterial disease – disease of blood vessels supplying the arms and legs
  • rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria
  • congenital heart disease – malformations of heart structure existing at birth
  • deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs

How can Randox help with these current global challenges

Cardiovascular disease, including heart disease, is easier to treat when detected early. Here at Randox, we utilise innovative diagnostic tests for early risk assessment capable of diagnosing disease at the earliest possible stages, because we understand that “prevention is better than cure”.

Randox Laboratories is a world leader in innovative diagnostics with 40 years’ experience and a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Randox offer an extensive menu of cardiac biomarkers within the cardiology reagents panel including:

Risk Assessment

  • CK-MB – useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
  • Myoglobin – a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
  • Routine lipid tests to determine the patient’s cholesterol and triglyceride levels HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
  • Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
  • Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy because of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
  • Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.

More information

If you are a clinician or lab interested in our Cardiology & Lipids Panel, we have a wealth of resources available:

Download our Reagents Brochure 

Download our Cardiology & Lipid Testing Brochure

If you would like to get in touch with a Sales representative please email us reagents@randox.com

 

 

Cardiac QC

Acusera Cardiac Controls is designed to deliver an assayed solution for Tropinin I and NT-proBNP testing. Its intended use with Roche, Abbott and Siemens. This control is manufactured using only the highest quality material and offers a 7-day thawed stability at +2ºC to +8ºC.

Four levels are available covering the clinically relevant range, including High Sensitivity Troponin I.

Features and Benefits

  • Liquid for ease-of-use stability
  • Aqueous material
  • 4 Clinically relevant levels (including Ultra-Low)
  • Stable to expiry date at -18-24ºC storage
  • Thawed stability of 7 days at 2°C – 8°C

For more information, visit our Cardiac Quality Control website 

If you have any other queries, don’t hesitate on contacting us at qualitycontrol@randox.com

Heart Health Test

High Cholesterol is a major risk factor for heart disease and stroke therefore at Randox Health we have the Heart Health Test to keep our cholesterol at a healthy level. This is done from the convenience of your home with our home sample collection kit. Heart Health measures your total cholesterol, HDL (good) cholesterol, LDL (bad cholesterol) and triglycerides.

Why we get tested?

There is so much importance in identifying cholesterol imbalance early which allows you to make appropriate dietary and lifestyle changes which in turn reduces your risk of heart disease and stroke. It is essential to acknowledge that regardless of your age and physical health, anyone can have high cholesterol; high levels may be a result of genetics or lifestyle which can often display with no underlying symptoms. Those with a family history of heart disease, who are overweight/ obese, drink alcohol, smoke regularly, lead a sedentary lifestyle or have diabetes are at an increased risk and should get tested.

Find out more here

Want to know more about Randox?

Contact us or visit our homepage to view more.


World Heart Day 2021

World Heart Day 2021

World Heart DAy 2021

World Heart Day – Raising awareness of Cardiovascular Diseases

World Heart Day was established by the World Heart Federation in collaboration with the World Health Organization to raise awareness of cardiovascular diseases.

Cardiovascular disease (CVD) is the world’s number one killer, causing over 18.6 million deaths per year, according to the World Heart Federation. 85% of these deaths are due to coronary heart diseases (e.g. heart attacks) and cerebrovascular diseases (e.g. strokes) and mostly affect low-and middle-income countries.

What are cardiovascular diseases?

Cardiovascular diseases (CVDs) are a group of disorders relating to the heart and blood vessels and they include:

  • coronary heart disease – disease of the blood vessels supplying the heart muscle
  • cerebrovascular disease – disease of the blood vessels supplying the brain
  • peripheral arterial disease – disease of blood vessels supplying the arms and legs
  • rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria
  • congenital heart disease – malformations of heart structure existing at birth
  • deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs

How can Randox help with these current global challenges

Cardiovascular disease, including heart disease, is easier to treat when detected early. Here at Randox, we utilise innovative diagnostic tests for early risk assessment capable of diagnosing disease at the earliest possible stages, because we understand that “prevention is better than cure”.

Randox Laboratories is a world leader in innovative diagnostics with 40 years’ experience and a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Randox offer an extensive menu of cardiac biomarkers within the cardiology reagents panel including:

Risk Assessment

  • CK-MB – useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
  • Myoglobin – a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
  • Routine lipid tests to determine the patient’s cholesterol and triglyceride levels HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
  • Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
  • Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy because of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
  • Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.

More information

If you are a clinician or lab interested in our Cardiology & Lipids Panel, we have a wealth of resources available:

Download our Reagents Brochure 

Download our Cardiology & Lipid Testing Brochure

If you would like to get in touch with a Sales representative please email us reagents@randox.com

Want to know more about Randox?

Contact us or visit our homepage to view more.


Veterinary Diagnostic Solutions

Veterinary Diagnostic Solutions

Comprehensive Clinical Packages for Veterinary Laboratories

Benefits of the Randox Veterinary Diagnostic Solutions

Validated icon

Validated for use

The Randox veterinary diagnostic solutions are scientifically proven and validated for use with a diverse range of animal species.

Complete Solutions

Complete Solutions

Encompassing diagnostic reagents, internal & external quality control, and the RX series of clinical chemistry analysers.

Applications Available

Applications Available

Applications available detailing instrument-specific settings for the convenient use of the Randox veterinary reagents on a variety range of clinical chemistry analysers.

Analyser

Analysers for all laboratories

With a range of semi-automated and automated analysers, the RX series offers versatility to suit the needs of all laboratory requirements.

Small sample volume

Small Sample Volume

Veterinary testing is one of Randox’s specialities and the RX series caters for smaller animals where samples can be harder to obtain with volumes ranging from 0.5 – 5μl.

Superior Performance

Superior Performance & Unique Tests

A range of superior performance & unique tests, offering veterinary laboratories choice, quality and innovation.

With almost 40 years’ experience in veterinary diagnostics – we can help!

MEDLAB ICONS-04
  • Clinical Chemistry Analysers

    Offering the world’s largest veterinary test menu, the RX series provides laboratories with maximum analyser up-time combined with precise, reliable and accurate results. With a diverse range of versatile semi-automated and fully automated analysers, the RX series suits the needs of all laboratory sizes with unrivalled correlation to gold-standard methodologies.

Learn More
MEDLAB ICONS-02
  • Diagnostic Reagents

    Offering an extensive veterinary test menu, encompassing 48 open channel diagnostic assays which are internationally recognised as being of the highest quality, producing accurate and precise results. All our assays are validated against gold-standard methods, offering low CV’s and excellent precision giving you the confidence that you are sending out the correct patient results.

Learn More
MEDLAB ICONS-03
  • Internal Quality Control

    As one of the largest manufacturers of true third party quality control solutions, Randox produce high quality materials that can help streamline laboratory procedures whilst saving time and money. With over 390 parameters available in our Acusera Internal Quality Control range, choice and flexibility is guaranteed. You can rely on Randox to deliver trustworthy results time and time again.

Learn More
MEDLAB ICONS-11
  • External Quality Assessment

    Randox International Quality Assessment Scheme (RIQAS) is the world’s largest external quality assessment (EQA) scheme. Currently offering 33 programmes, RIQAS has more than 45,000 laboratory participants in over 130 countries. Delivering a comprehensive yet cost effective EQA solution, RIQAS will help meet regulatory requirements and increase confidence in test system accuracy.

Learn More

Diagnostic Veterinary Reagents

RX series Clinical Chemistry Analysers


Cardiac Risk

CVD

Your heart is amazing. Not only is it your most critical organ but also one of the most hard-working. The average adult heart beats around 100,000 times a day, acting as a giant pump for all the blood in your body. Indeed, every day your heart pumps over nine litres of blood through a system of blood vessels over 60,000 miles long – it’s little wonder, then, the importance placed on looking after such a vital muscle.

Did you know?

Cardiovascular Diseases (CVDs) are the number 1 cause of death globally, more people die annually from CVDs than any other cause.

 

Over time, and influenced by lifestyle choices, the heart grows weaker, needing to work harder to fulfil its function. Crucial lifestyle changes now could limit your risk of developing serious cardiac conditions, such as Cardiovascular Disease (CVD) in the future.

While lifestyle changes may help to limit your risk of CVD, and related heart condition, it is impossible to eradicate it completely for everyone. Cardiovascular disease is the number one cause of death globally. Across the world, 17.7 million people died from CVDs in 2015. In the UK, it accounts for nearly one death around every eight minutes.

But early screening and improved access to cutting-edge diagnostics could lower this figure significantly. According to the WHO there are 8 key risk factors of developing CVD and they account for as much as 61% of all cardiovascular deaths, these include;

Smoking

The harmful substances in tobacco can damage and narrow blood vessels, causing CVDs. Smoking kills approximately half of persistent smokers, around 14% of deaths from circulatory disease can be attributed to smoking.

High Blood Pressure

High blood pressure (hypertension) is one of the most important risk factors of CVD, if your blood pressure is too high your blood vessels can become damaged.

High BMI

Being overweight or obese increases the risk of developing diabetes and high blood pressure, both of which can cause CVD. You’re at an increased risk of CVD if your BMI is 25 or above.

High Cholesterol

Cholesterol is a fatty substance found in the blood, high levels of cholesterol can cause blood vessels to narrow and increase the risk of developing a blood clot. Reducing the populations LDL-Cholesterol by 5% would prevent 64,000 cases of CVD.

Lack of Physical Activity

If you don’t exercise regularly, it’s more likely you’ll develop high blood pressure, high cholesterol levels and become overweight. All of which are risk factors of CVD. Exercising regularly helps to keep the heart healthy.

Other CVD risk factors include an excessive alcohol intake, an unhealthy diet and high levels of blood glucose.

Related Products 

Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many tests for the diagnosis and monitoring of cardiac diseases.

Cardiac Panel

Cholesterol CRP Full Range(0.3-160mg/l) Direct LDL Cholesterol sLDL
CK-MB CRP High Sensitivity Heart-Type Fatty Acid Binding Protein (H-FABP) Triglycerides
CK-NAC Digoxin Lipoprotein(a) TxB Cardio
CRP Direct HDL Cholesterol Myoglobin

 

Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.

The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.

For more information visit: https://www.randox.com/clinical-chemistry-analysers/

 

 

Cardiac health and regular cardiovascular screening is important to enable risk factors to be detected in their earliest stages. Randox reagents offer a comprehensive cardiology product profile which includes high performance reagents for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.

sLDL cholesterol

sLDL cholesterol  is a vital cardiac risk marker which utilises the “Denka Seiken” method which produces results in less than ten minutes. Research has shown individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction (MI), even for those who HDL, LDL, Total Cholesterol and Triglyceride levels are considered ‘normal’. Elevated levels of sLDL are associated with a sedentary lifestyle, a diet high in saturated fat, insulin resistance, pre-diabetes and genetic disposition. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels reduce the risk of both CVD and MI.

For more information visit: www.randox.com/sldl-cholesterol/

Lipoprotein (a)

Lipoprotein (a) is a major independent genetic risk factor for premature CVD and elevated levels can occur in patients with otherwise normal lipid levels, therefore providing much needed information in relation to a patient’s risk of developing CVD.Along with other tests, Lp(a) can provide additional information on a patient’s risk factor of developing cardiovascular disease (CVD).

The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias providing more accurate and consistent results.

For more information visit: www.randox.com/lipoprotein-a/

HDL3 Cholesterol

HDL3 Cholesterol is a smaller and more dense sub fraction of the HDL particle. HDL comprises of several subclass particles, which differ in their sizes, densities and components. HDL is the scavenger of cholesterol within arterial walls and the levels of HDL3 is too low, the ability to remove this cholesterol is reduced. Therefore, it is widely accepted that there is an inverse correlation between HDL3 and cardiovascular disease risk.

For more information visit: https://www.randox.com/hdl3/

 

Cardiology and Lipid Testing Panel

  • Apolipoprotein A-I
  • Apolipoprotein A-II
  • Apolipoprotein B
  • Apolipoprotein C-II
  • Apolipoprotein C-III
  • Apolipoprotein E
  • Cholesterol (sLDL)
  • Cholesterol (HDL)
  • Cholesterol (LDL)
  • Cholesterol (Total)
  • Cholesterol (HDL3)
  • Lipoprotein (a)
  • High sensitivity CRP
  • Homocysteine
  • Triglycerides
  • HDL3-C
  • sPLA₂-IIA
  • Heart Type Fatty Acid Binding Protein (H-FABP)
  • CK-MB
  • Myoglobin
  • Digoxin
  • TxBCardio™

Browse our full cardiology and lipid testing panel here.

To request an application for your specific analyser, contact us at reagents@randox.com

When diagnosing and monitoring CVD, it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. The Acusera Cardiac Controls have been designed to cover a wide range of cardiac markers at clinical decision levels eliminating the need for additional low level controls at extra expense. Available in both liquid ready-to-use and lyophilised formats, they are ideal for use at the point-of-care and in the laboratory. Manufactured from 100% human serum a matrix similar to that of the patient is guaranteed.

Liquid Cardiac Control

  • Liquid ready-to-use
  • 100% human serum
  • Assayed target values provided for 8 cardiac markers
  • Cut off levels for Troponin I and T in line with internationally recommended levels
  • Stable to expiry date at 2°C – 8°C
  • Open vial stability of 30 days at 2°C – 8°C for all analytes

Analytes

Myoglobin Troponin I Troponin T
NT – ProBNP CK-MB (Mass) D-dimer
Digoxin hsCRP

Find out more about our Liquid Cardiac Quality Control here.

Other cardiac quality controls include:

For more information, visit our Cardiac Quality Controls page.

RIQAS Cardiac Programme

The RIQAS Cardiac EQA programme is designed to monitor the performance of up to 7 clinically significant cardiac markers. Two flexible reporting options are available to suit the needs of all laboratory sizes.

  • Accredited to ISO/IEC 17043
  • Lyophilised for enhanced stability
  • 100% human serum
  • Bi-weekly reporting
  • Submit results and view reports online via RIQAS.Net
  • Register up to five instruments at no extra cost

For more information, visit our RIQAS Cardiac Programme page.

Our Randox Health clinics offer comprehensive health testing as part of our Signature, Everyman and Everywoman packages to identify and assess risk of developing Cardiovascular Disease. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).

For more information visit: https://www.randoxhealth.com/

follow us on social media


Medlab Middle East

Join us for Medlab Middle East 2020!

 

Randox Laboratories will be attending Medlab Middle East form the 3rd February – 6th February 2020. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Dubai International Convention & Exhibition Centre at stand Z5.B10.

 

New Products

  • Serology Controls
  • Stroke Biochip
  • Lipoprotein(a)
  • H-FABP in CSA-AKI Testing
  • Acusera Verify
  • Evidence+

Acusera Infectious Disease Serology Controls

Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.

All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.

There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.

The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.

Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.

Randox Stroke Biochip

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Benefits of the Randox Stroke Biochip

> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample

> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis

> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke

> Simple 2 step process from sample entry to results

> Ensures better outcomes guaranteeing timely therapeutic intervention

Lipoprotein(a) [Lp(a)]

 Lipoprotein(a) [Lp(a)] is described as “the most complex and polymorphic of the lipoprotein particles” 1. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms. Standardisation across calibrators is vital as the repeated KIV-2 units in Lp(a) act as multiple epitopes. A lack of standardisation could result in the underestimation of Lp(a) associated CVD risk 2.

Lp(a) assays that are standardised to the WHO/IFCC reference material, transferring values from mg/dl to nmol/l are more uniformed. The Denka Seiken Lp(a) assay is the most reliable commercially available Lp(a) assay, because 2:

  1. The isoform size variations are reduced as a range of calibrators from separate pools of serum were used which covered a range of Lp(a) concentrations.
  2. The isoform size and concentrations are inversely correlated better matching calibrants with test samples.
  3. Methods based on the Denka Lp(a) assay, calibrated in nmol/l and traceable to the WHO/IFCC reference material produced an acceptable bias compared with the Northwest Lipid Metabolism and Diabetes Research Laboratory (NLMDRKL) gold standard method.

 

HEART UK advocate the widespread clinical utility of Lp(a) to refine the CVD risk assessment. In doing so, HEART UK developed ten statements on Lp(a) (Table 1) utilising the 2016 ACC/AHA Clinical Guideline Recommendation Classification System, to assess the strength of the recommendation and aid in guiding the phrasing of the recommendation 2.

Key Features of the Randox Lp(a) Assay

  • The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias providing more accurate and consistent results. The Randox Lp(a) kit is standardised to the WHO/IFCC reference material (IFCC SRM 2B) and is closest in terms of agreement to the ELISA reference method.
  • Five-point calibrator with accuracy-based assigned target values, and control are available, accurately reflecting the heterogeneity of the apo(a) isoforms present in the general population and offering a complete testing package.
  • Measuring units are available in nmol/l which is more uniformed and recommended by HEART UK.
  • Immunoturbidimetric method is highly sensitive and specific for the detection of Lp(a) in serum and plasma.
  • Excellent correlation co-efficient of r=0.995 when compared against other commercially available methods.
  • Excellent within run precision of <2.54%.
  • Liquid ready-to-use format for convenience and ease-of-use.
  • Applications available detailing instrument-specific settings for the convenient use of the Randox Lp(a) assay on a wide range of clinical chemistry analysers.

 

References

  1. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application . Journal of Lipid Research 2019; 57(): 526-537.
  2. Cegla J, Dermot R, Neely G, France M, Ferns G, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291(): 62-70.

H-FABP in CSA-AKI Testing

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the ICU, occurring in up to 30% of patients. Higher pre-operative values of H-FABP were associated with a higher risk of developing AKI. Following adjustments of certain patient characteristics, the association of pre-operative H-FABP with the development of AKI remained significant. In fact, the researchers observed that a 1 unit increase in log H-FABP was associated with a 3-fold increase in the odds of developing AKI.

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

The new Evidence+

The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.

The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.

What can we offer?

  • Biosciences
  • Quality Control
  • EQA
  • QCMD
  • Qnostics
  • Reagents
  • Evidence Series
  • RX Series
  • Toxicology
vivalytic

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.

Vivalytic

Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic  a unique space-saving, hygienic solution for Molecular Diagnostic testing.

Leading provider of true third-party controls

With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimize waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.

Online QC software with real-time peer group statistics

Designed to help you efficiently review QC data from multiple laboratory instruments on one centralized platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.

Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.

Book a live demonstration for Acusera 24.7

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

RIQAS – The World’s Largest International PT scheme

With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international PT provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programmes required whilst increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.

QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases.

With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics.

Molecular Infectious Disease Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 117 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.

Randox are continuously striving to improve diagnostic solutions worldwide.  As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.

Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.

Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.

RX misano

The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.

RX monaco

The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.

RX daytona +

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.

RX imola

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most

RX modena

Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.

Find out more about Direct HbA1c
Book a demonstration of one of our analysers

Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.

Want to know more?

Contact us or book a meeting with us





Medica 2019

Join us for MEDICA 2019!

 

 

Randox Laboratories will be attending MEDICA 2019 from the 18th – 22nd November 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Messe Düsseldorf, Germany.

New Products

  • Serology Controls
  • Adiponectin
  • Stroke Biochip
  • Evidence+
  • Acusera Verify
  • H-FABP in CSA-AKI Testing

Acusera Infectious Disease Serology Controls

Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.

All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.

There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.

The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.

Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.

Adiponectin

Adiponectin (adipocyte complement-related protein of 30kDa (Acrp30)) is an adipokine (protein hormone) produced and secreted by the adipose tissue, an endocrine organ. Adiponectin acts as a messenger in the communication of adipose tissue and metabolic organs. In doing so, Adiponectin suppresses the production of glucose in the liver through inhibiting the genes involved in glucose production and enhances fatty acid oxidation in skeletal muscle 2. Consequently, Adiponectin is a strong protector against several pathological events in various cells through inhibiting inflammation, suppressing cell death and enhancing cell survival. Adiponectin has been identified as having pleiotropic functions widely associated with anti-atherogenic, anti-diabetic, cardioprotective and anti-inflammatory effects.

Randox Stroke Biochip

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Benefits of the Randox Stroke Biochip

> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample

> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis

> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke

> Simple 2 step process from sample entry to results

> Ensures better outcomes guaranteeing timely therapeutic intervention

The new Evidence+

The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.

The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

H-FABP in CSA-AKI Testing

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the ICU, occurring in up to 30% of patients. Higher pre-operative values of H-FABP were associated with a higher risk of developing AKI. Following adjustments of certain patient characteristics, the association of pre-operative H-FABP with the development of AKI remained significant. In fact, the researchers observed that a 1 unit increase in log H-FABP was associated with a 3-fold increase in the odds of developing AKI.

What can we offer?

  • Biosciences
  • Acusera
  • RIQAS
  • Qnostics
  • Reagents
  • RX Series
  • Toxicology
  • Evidence Series
vivalytic

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.

Vivalytic

Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic  a unique space-saving, hygienic solution for Molecular Diagnostic testing.